Michael A. Weber

45.1k total citations · 7 hit papers
499 papers, 21.9k citations indexed

About

Michael A. Weber is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Michael A. Weber has authored 499 papers receiving a total of 21.9k indexed citations (citations by other indexed papers that have themselves been cited), including 377 papers in Cardiology and Cardiovascular Medicine, 163 papers in Endocrinology, Diabetes and Metabolism and 93 papers in Surgery. Recurrent topics in Michael A. Weber's work include Blood Pressure and Hypertension Studies (335 papers), Hormonal Regulation and Hypertension (143 papers) and Heart Rate Variability and Autonomic Control (80 papers). Michael A. Weber is often cited by papers focused on Blood Pressure and Hypertension Studies (335 papers), Hormonal Regulation and Hypertension (143 papers) and Heart Rate Variability and Autonomic Control (80 papers). Michael A. Weber collaborates with scholars based in United States, Germany and United Kingdom. Michael A. Weber's co-authors include George L. Bakris, Stevo Julius, Jan I.M. Drayer, John H. Laragh, Sverre E. Kjeldsen, Stanley S. Franklin, Tsushung A. Hua, Daniel Levy, Martin G. Larson and William Gustin and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Michael A. Weber

490 papers receiving 20.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

2004 1.8k citations Stevo Julius, Sverre E. Kjeldsen et al. profile →
Hemodynamic Patterns of Age-Related Changes in Blood Pressure

1997 1.7k citations Michael A. Weber et al. Circulation profile →
Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients

2008 1.3k citations Kenneth Jamerson, Michael A. Weber et al. profile →
Feasibility of Treating Prehypertension with an Angiotensin-Receptor Blocker

2006 619 citations Stevo Julius, Brent M. Egan et al. profile →
ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly

2011 406 citations George L. Bakris, Keith C. Ferdinand et al. Circulation profile →
Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial

2022 168 citations Felix Mahfoud, David E. Kandzari et al. profile →
Hypertension management in patients with cardiovascular comorbidities

2022 91 citations Lucas Lauder, Felix Mahfoud et al. European Heart Journal profile →

Peers

Countries citing papers authored by Michael A. Weber

Since Specialization

Citations

This map shows the geographic impact of Michael A. Weber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael A. Weber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael A. Weber more than expected).

Fields of papers citing papers by Michael A. Weber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael A. Weber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael A. Weber. The network helps show where Michael A. Weber may publish in the future.

Co-authorship network of co-authors of Michael A. Weber

This figure shows the co-authorship network connecting the top 25 collaborators of Michael A. Weber. A scholar is included among the top collaborators of Michael A. Weber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael A. Weber. Michael A. Weber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Low Achieved Systolic Blood Pressure Related to Kidney Protection in Diabetic and Non-Diabetic High-Risk Hypertensive Patients 2025 ·American Journal of Hypertension ·(unknown), Camilla Lund Søraas, Roland E. Schmieder, Kenneth Jamerson, Thomas M. MacDonald, Giuseppe Mancia, (unknown), Maria H. Mehlum, Knut Liestøl, Anne Cecilie K. Larstorp, Julian E. Mariampillai, (unknown), (unknown), Aud Høieggen, Morten Rostrup, (unknown), Michael A. Weber	1
2	PERSPECTIVE – The Growing Global Benefits of Limiting Salt Intake: an urgent call from the World Hypertension League for more effective policy and public health initiatives 2025 ·Journal of Human Hypertension ·Brent M. Egan, Daniel T. Lackland, Susan E. Sutherland, Michael Rakotz, Janet Williams, Yvonne Commodore‐Mensah, Daniel W. Jones, Sverre E. Kjeldsen, Norm R.C. Campbell, Gianfranco Parati, Feng J. He, Graham A. MacGregor, Michael A. Weber, Paul K. Whelton	0
3	Novel approaches to define responders to interventional treatment in hypertension: insights from the SPYRAL HTN-OFF and HTN-ON MED trials 2024 ·Hypertension Research ·Roland E. Schmieder, Douglas A. Hettrick, Michael Böhm, David E. Kandzari, Kazuomi Kario, Felix Mahfoud, Konstantinos Tsioufis, Michael A. Weber, Murray Esler, Raymond R. Townsend	2
4	SIGNIFICANT NIGHTTIME BLOOD PRESSURE REDUCTIONS AFTER RADIOFREQUENCY RENAL DENERVATION IN PATIENTS WITH UNCONTROLLED HYPERTENSION: POOLED ANALYSIS OF THE SPYRAL HTN TRIALS 2024 ·Journal of Hypertension ·(unknown), Felix Mahfoud, Raymond R. Townsend, David E. Kandzari, Michael A. Weber, Roland E. Schmieder, Konstantinos Tsioufis, Martin Fahy, Michael Böhm	1
5	Effect of Alcohol-Mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Medications: Primary Results From the TARGET BP I Randomized Clinical Trial 2024 ·Circulation ·David E. Kandzari, Michael A. Weber, Atul Pathak, James P. Zidar, Manish Saxena, Shukri David, Roland E. Schmieder, Adam Janas, (unknown), Alexandre Persu, Farrell O. Mendelsohn, Koen Ameloot, Malcolm Foster, Tim A. Fischell, Helen Parise, Felix Mahfoud	26
6	Cardiovascular Outcomes in Hypertension-Treated Patients With Peripheral Artery Disease: The VALUE Trial 2024 ·Hypertension ·Mislav Vrsalović, (unknown), Camilla Lund Søraas, Maria H. Mehlum, Sverre E. Kjeldsen, Giuseppe Mancia, Stevo Julius, Michael A. Weber	2
7	Middle-Aged and Older Patients With Left Ventricular Hypertrophy: Higher Mortality With Drug Treated Systolic Blood Pressure Below 130 mm Hg 2023 ·Hypertension ·(unknown), Maria H. Mehlum, Giuseppe Mancia, Camilla Lund Søraas, Knut Liestøl, Kristian Wachtell, Anne Cecilie K. Larstorp, Morten Rostrup, Julian E. Mariampillai, Sverre E. Kjeldsen, Stevo Julius, Michael A. Weber	13
8	Hypertension management in patients with cardiovascular comorbidities breakdown → 2022 ·European Heart Journal ·Lucas Lauder, Felix Mahfoud, Michel Azizi, Deepak L. Bhatt, Sebastian Ewen, Kazuomi Kario, Gianfranco Parati, Patrick Rossignol, Markus P. Schlaich, Koon Teo, Raymond R. Townsend, Costas Tsioufis, Michael A. Weber, Thomas Weber, Michael Böhm	91
9	A re-examination of the SPYRAL HTN-OFF MED Pivotal trial with respect to the underlying model assumptions 2021 ·Contemporary Clinical Trials Communications ·Michael Böhm, Martin Fahy, Graeme L. Hickey, Stuart Pocock, Sandeep Brar, Vanessa DeBruin, Michael A. Weber, Felix Mahfoud, David E. Kandzari	6
10	Catheter-based alcohol-mediated renal denervation for the treatment of uncontrolled hypertension: design of two sham-controlled, randomized, blinded trials in the absence (TARGET BP OFF-MED) and presence (TARGET BP I) of antihypertensive medications 2021 ·American Heart Journal ·Felix Mahfoud, Michael A. Weber, Roland E. Schmieder, Melvin D. Lobo, Peter J. Blankestijn, Alexandre Persu, Tim A. Fischell, Helen Parise, Atul Pathak, David E. Kandzari	19
11	Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus and hypertension 2021 ·Blood Pressure ·(unknown), Björn Holzhauer, Stevo Julius, Sverre E. Kjeldsen, Anne Cecilie K. Larstorp, Giuseppe Mancia, Maria H. Mehlum, (unknown), Morten Rostrup, Camilla Lund Søraas, Dion Zappe, Michael A. Weber	3
12	Long-Term Results up to 12 Months After Catheter-Based Alcohol-Mediated Renal Denervation for Treatment of Resistant Hypertension 2021 ·Circulation Cardiovascular Interventions ·Felix Mahfoud, Horst Sievert, Stefan Bertog, Lucas Lauder, Sebastian Ewen, Jean‐Philippe Lengelé, Wojciech Wojakowski, Roland E. Schmieder, Markus van der Giet, Michael A. Weber, David E. Kandzari, Helen Parise, Tim A. Fischell, Atul Pathak, Alexandre Persu	9
13	Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus compared to all middle-aged and elderly hypertensive study patients with high cardiovascular risk 2021 ·Blood Pressure ·(unknown), Björn Holzhauer, Stevo Julius, Sverre E. Kjeldsen, Anne Cecilie K. Larstorp, Giuseppe Mancia, Maria H. Mehlum, (unknown), Morten Rostrup, Camilla Lund Søraas, Dion Zappe, Michael A. Weber	5
14	Cardiovascular Safety of the β₃‐Adrenoceptor Agonist Mirabegron and the Antimuscarinic Agent Solifenacin in the SYNERGY Trial 2018 ·The Journal of Clinical Pharmacology ·William B. White, Christopher R. Chapple, Christian Gratzke, Sender Herschorn, Dudley Robinson, Jeffrey Frankel, Arwin Ridder, Matthias Stoelzel, Asha Paireddy, (unknown), Michael A. Weber	17
15	Comparison of Effectiveness of Azilsartan Medoxomil and Olmesartan in Blacks Versus Whites With Systemic Hypertension 2018 ·The American Journal of Cardiology ·Keith C. Ferdinand, George L. Bakris, William C. Cushman, Michael A. Weber, Eric Lloyd, Jingtao Wu, William B. White	4
16	Combining RAAS and calcium channel blockade: ACCOMPLISH in perspective 2008 ·Blood Pressure ·Sverre E. Kjeldsen, Michael A. Weber, Suzanne Oparil, Kenneth Jamerson	3
17	What Do Students Want? A Focus Group Study of Students at a Mid-Sized Public University 2008 ·Library philosophy and practice ·Michael A. Weber, (unknown)	10
18	Expanding the opportunities for blocking the renin-angiotensin system: introduction to a special supplement. 2007 ·PubMed ·Michael A. Weber	2
19	Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy? 2006 ·PubMed ·Michael A. Weber, Thomas D. Giles	42
20	Place of Calcium Antagonists in Antihypertensive Therapy 1984 ·Journal of Cardiovascular Pharmacology ·(unknown), (unknown), (unknown), (unknown), Gloría Valdés, Michael A. Weber	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact